MedPath

Research on clinical development of a new clinical outcome (major pathological response) for preoperative treatment of lung cancer using artificial intelligence

Not Applicable
Conditions
on-small cell lung cancer patients who received preoperative treatment at our hospital from April 2002 to April 2021 and subsequently underwent surgery
Registration Number
JPRN-UMIN000047486
Lead Sponsor
Shizuoka Cancer Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

There are no specific exclusion criteria.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relationship between PR and MPR evaluated by artificial intelligence and MPR and PR evaluated by pathologists
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath